Ventyx Q1 2024 net loss $38.6M; cash $302.6M; Phase 2a trials in H2 2024

Ventyx Biosciences, Inc.

2024-Q1 EPS reported -$0.62

Net loss of $38.6M in Q1 2024 vs $38.9M in Q1 2023; R&D $33.7M, G&A $8.0M.
Cash, cash equivalents and marketable securities of $302.6M as of March 31, 2024; runway into H2 2026.
Phase 2a trials of CNS-penetrant NLRP3 inhibitor VTX3232 to start H2 2024 in early Parkinson's and obesity with CV risk factors.
Phase 2 topline data for TYK2 inhibitor VTX958 in Crohn's disease expected early H2 2024; enrollment completed.
Positive Phase 2 CAPS data for VTX2735; seeking partner for VTX002 Phase 3 in ulcerative colitis.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Ventyx Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

today announced financial results for the first quarter ended March 31, 2024

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-056914

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.